The malaria essence is that parasites enter the liver through the blood and destroy red blood cells. Even though more than a century of international work and study has improved malaria prevention, diagnosis, and treatment, plasmodium falciparum still kills over 400 000 people annually (Talapko et al., 2019). The genetic resistance to the disease is new information on the topic. For instance, Muhammad et al. (2022) state that genetic variables are responsible for around 25% of the overall variation in malaria incidence. The discussion could be moved forward with the treatment of the disease. For instance, malaria vaccinations have already entered the clinic by testing transmission-blocking vaccines that kill mosquitoes—advanced to field trials (Duffy & Gorres, 2020). Moreover, Draper et al. (2018) state that new advancements in malaria vaccine development give a reason for hope. This will result in quantitatively and qualitatively better immune effector mechanisms.
References
Duffy, P. E. & Gorres, J. P. (2020). Malaria vaccines since 2000: Progress, priorities, products. Npj Vaccines, 5.
Draper, S. J., Sack, B. K., King, C. R., Nielsen, C. M., Rayner, J. C., Higgins, M. K., Long, C. A., Seder, R. A. (2018). Malaria vaccines: Recent advances and new horizons. Cell Host & Microbe, 24(1), 43-56.
Muhammad, I., Abubakar, B., & Muhammad, T. M. (2022). Genetic resistance to human malaria. Cellular, Molecular and Biomedical Reports, 2(2), 116-128.
Talapko, J., Škrlec, I., Alebić, T., Jukić, M., & Včev, A. (2019). Malaria: The past and present. Microorganisms,7(6), 179.